'Cool' Technology for Breast Biopsy Enthusiastically Welcomed by Breast Care
Physicians
PLEASANTON, Calif., Dec. 1 /PRNewswire/ -- Physicians and their breast
care patients now have a "cool" minimally invasive alternative to traditional
breast biopsy devices. Sanarus Medical, Inc. announces the market release of
the Cassi(TM) Rotational Core Biopsy Device, which is based on the company's
proprietary Stick Freeze Technology(TM).
More than 1.6 million breast biopsies are performed each year in the
United States. A biopsy may be prescribed when the patient's breast care
physician detects a breast lump or abnormality. The procedure involves taking
tissue samples or "cores" from the suspicious area to determine if the lump is
cancerous.
The Cassi Biopsy Device is the first hand-held large-core biopsy device on
the market to be fully automated and disposable post procedure. It requires no
set-up time, performs quickly, and requires no capital equipment investment,
which means significant time and cost savings to physicians.
FDA-cleared, Cassi is ultrasound guided and uses proprietary Stick Freeze
Technology(TM) to deliver large, precise tissue samples with fewer passes.
Procedurally, Cassi is first introduced into the breast lump or "lesion." Once
in place, Cassi quickly immobilizes the lesion with a "stick freeze" that
secures the targeted tissue to the biopsy needle. A cutting cannula then
rotates quickly over the needle to obtain the tissue sample. Larger tissue
samples are proving more reliable than fine-needle aspirations in helping
physicians more accurately diagnose the nature of the lesion.
When a suspicious breast lump is detected during a physician office visit,
Cassi can be used to perform a biopsy immediately, with local anesthesia. This
may eliminate the need to schedule a return visit to perform the biopsy, and
is less stressful for patients.
Prior to market release of Cassi, Sanarus conducted a survey among
physicians who used the device to perform a collective of 100 biopsies. In
comparing Cassi's performance to that of previously available biopsy devices,
physicians gave high marks to Cassi for ease-of-use, patient use, set up,
penetration of varying types of breast lesions, and the size of tissue samples
retrieved.
Dr. Angela Soto Hamlin of Lemoyne, Pennsylvania, is a private-practice
breast care surgeon. According to Dr. Soto Hamlin, "Recently, Cassi proved
instrumental in helping me obtain a quality tissue specimen from one of my
patients. From this specimen I was able to make a more accurate diagnosis,
one that helped me avoid the delay of scheduling her biopsy for another day or
sending her to the operating room. I like the fact that Cassi is simple to
use, time-efficient, cost-effective, and, ultimately, helps me to determine
the best treatment plan for my patients."
The Cassi Rotational Biopsy Device will be launched in conjunction with
the upcoming RSNA Conference at the end of November.
About Sanarus Medical, Inc.
Headquartered in Pleasanton, California, Sanarus Medical is committed to
developing innovative products for minimally invasive diagnosis and treatment
of breast disease, utilizing its proprietary cryoablation technology.
Privately held, Sanarus Medical is funded by leading healthcare venture
capital investors. To request information regarding the Cassi Rotational Core
Biopsy Device or the Visica(TM) Treatment System for fibroadenomas, please
email info@sanarus.com.
SOURCE Sanarus Medical, Inc.
 back to top
Related links:
http://www.sanarus.com
CONTACT:
John Rush, President, CEO of Sanarus, Inc.,
+1-926-460-6080, or jrush@sanarus.com
|
